Compare Krispy Kreme Inc (DNUT) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs Heron Therapeutics Inc — how do they compare? Krispy Kreme Inc trades at $3.01 (market cap $508.36M), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Krispy Kreme Inc is far larger — about 6.9× Heron Therapeutics Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 45 Days and Heron Therapeutics Inc for 35 Days on average.
| DNUT | HRTX | |
|---|---|---|
Market Cap | $508.36M | $74.04M |
Volume | 1,955,706 | 3,668,095 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $1.49 |
52-Week Low | $2.87 | $0.27 |
Typical Hold Time | 45 Days | 35 Days |
Enterprise Value | $1.75B | $180.78M |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $3.01, down 0.33% on the day, with a bearish technical signal. The company reported a net loss of $515.77 million in 2025, despite a 75.19% gross margin, and faces legal investigations into fiduciary duties. Revenue declined to $1.52 billion in 2025 from $1.7 billion in 2024.
The outlook is cautious due to persistent losses and legal overhangs, though analyst consensus leans buy. Key risks include profitability challenges and high debt. Upside depends on operational turnaround and new product launches driving growth.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
